INFINITY PHARMACEUTICALS INC (INFI)       0.636  +0 (+0.13%)

0.636  +0 (+0.13%)

US45665G3039 - Common Stock - After market: 0.6576 +0.02 (+3.4%)


Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to INFI. INFI was compared to 641 industry peers in the Biotechnology industry. INFI has a bad profitability rating. Also its financial health evaluation is rather negative. INFI is quite expensive at the moment. It does show a decent growth rate.

Note: INFI has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

INFI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of INFI.

VS Industry

Valuation

Valuation Rating

0

The Price/Earnings Ratio is negative for INFI. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INFI. No positive earnings are expected for the next year.
VS Industry

Growth

Growth Rating

6

INFI shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.92%.
Based on estimates for the next 5 years, INFI will show a very strong growth in Revenue. The Revenue will grow by 59.76% on average per year.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.

INFI shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.14%.
INFI is expected to show a small growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 8.44% yearly.
Measured over the past 5 years, INFI shows a very negative growth in Revenue. The Revenue has been decreasing by -36.99% on average per year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 7.14% 14.36% 8.06% 8.44% N/A
Revenue-36.99% -56.19% 35.92% 55.5% 6.9% -1.48% 59.76%

Health

Health Rating

2

INFI has a Current Ratio of 3.48. This indicates that INFI is financially healthy and has no problem in meeting its short term obligations.
INFI has a Quick Ratio of 3.48. This indicates that INFI is financially healthy and has no problem in meeting its short term obligations.
Compared to an average industry Current Ratio of 6.18, INFI is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.05, INFI is worse placed to pay its short term obligations than its industry peers.

Based on the Altman-Z score of -24.56, we must say that INFI is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.10, INFI is in worse financial state than most of its industry peers. 95% of its industry peers have a better Altman-Z score.
INFI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of INFI.
VS Industry

Quick Ratio (3.48) VS Industry: 30% outperformed.

0.04
84.53

Current Ratio (3.48) VS Industry: 29% outperformed.

0.08
85.09

Altman-Z (-24.56) VS Industry: 5% outperformed.

-2,801.75
658.20

Dividend

Dividend Rating

0

No dividends for INFI!.

INFINITY PHARMACEUTICALS INC0.636

NASDAQ:INFI (2/3/2023, 7:00:03 PM)+0 (+0.13%)

After market: 0.6576 +0.02 (+3.4%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-14 2022-11-14/bmo Earnings (Next) 03-27 2023-03-27/amc
Inst Owners 34.73% Inst Owner Change 0.25%
Ins Owners 0.32% Ins Owner Change 0%
Market Cap 56.82M Analysts 80
Price Target 5.44 (755.35%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) -41.69%
Min EPS beat(2) -96.08% Max EPS beat(2) 12.7%
EPS beat(4) 2 Avg EPS beat(4) -19.86%
Min EPS beat(4) -96.08% Max EPS beat(4) 12.7%
Revenue beat(2) 1 Avg Revenue beat(2) -29.44%
Min Revenue beat(2) -88.72% Max Revenue beat(2) 29.84%
Revenue beat(4) 3 Avg Revenue beat(4) 18.24%
Min Revenue beat(4) -88.72% Max Revenue beat(4) 85.19%
PT rev (1m) 21.9% PT rev (3m) 12.28%
EPS NQ rev (1m) 39.4% EPS NQ rev (3m) 72.22%
EPS NY rev (1m) 0% EPS NY rev (3m) 1.11%
Revenue NQ rev (1m) -7.7% Revenue NQ rev (3m) 28.78%
Revenue NY rev (1m) 0% Revenue NY rev (3m) 7.34%

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.72
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM) -0.52 EY N/A
EPS(NY) -0.44 Fwd EY N/A
FCF(TTM) -0.48 FCFY N/A
OCF(TTM) -0.48 OCFY N/A
SpS 0.03 BVpS -0.12
TBVpS -0.12 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 39.7%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y -26.49% GM growth 5Y N/A
F-Score 3 Asset Turnover 0.05

Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.6%
Profit Quality N/A
Current Ratio 3.48
Quick Ratio 3.48
Altman-Z -24.56
F-Score 3 WACC 8.95%
ROIC/WACC N/A Cap/Depr(3y) 384.1%
Cap/Depr(5y) 230.46% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 7.14% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 0%
EPS Next Y 14.36% EPS Next 2Y 8.06%
EPS Next 3Y 8.44% EPS Next 5Y N/A
Revenue growth 1Y 35.92% Revenue growth 3Y -56.19%
Revenue growth 5Y -36.99% Revenue growth Q2Q 66.36%
Revenue Next Year 55.5% Revenue Next 2Y 6.9%
Revenue Next 3Y -1.48% Revenue Next 5Y 59.76%
EBIT growth 1Y -6.86% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year N/A
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y -17.89% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -20.14%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA